

A close-up photograph of a woman with blonde hair, wearing a white lab coat, focused on applying a cream from a black jar to a patient's arm. The background is softly blurred, suggesting a clinical or laboratory setting.

TREATING INFLAMMATION AT THE SOURCE


with **AMTX-100**

THE POWER OF IMMUNOTHERAPEUTIC PEPTIDES

Introducing the water-based peptide formula AMTX-100 with the potential to heal skin disorders.



At Amytrx Therapeutics, we take inflammation seriously. Systemic and local inflammation are the underlying cause of many diseases and yet there are no great treatments out there that combine efficacy and long-term tolerability. Many of the current therapeutics on the market have issues of safety. Patients deserve an effective treatment that doesn't cause harmful effects typical of traditional steroids. Fortunately, we are on the cusp of a breakthrough with the healing power of a safe, effective, and easy-to-use peptide cream that can help the body heal by downplaying an overactive immune response right at the source.



Dermatology Trends

Are JAK Inhibitors Really the Future of Inflammatory Skin Disease Therapeutics?

The American Journal of Managed Care announced earlier this year that 2023 was the 'Year of JAK Inhibitors in Dermatology.' Though JAK inhibitors may show potential against more traditional steroid therapeutics, they're not without their downfalls. [A recent review](#) on their safety shows that many JAK/STAT inhibitors used to treat inflammatory skin diseases like atopic dermatitis or alopecia still have a risk for certain adverse effects.

"WE KNOW WE CAN DO BETTER."
SAYS CEO DR. GONDA
OF AMYTRX
THERAPEUTICS.


The most common adverse events of oral JAK inhibitors included upper respiratory infections, nasopharyngitis, nausea, headache, and acne.



BREAKTHROUGH AMYTRX UPDATE:

Our adult Atopic Dermatitis clinical trial is coming to a close.

Earlier this year we announced open enrollment in our Phase 2b to treat mild to moderate atopic dermatitis with our novel topical formula containing the anti-inflammatory peptide, AMTX-100. This trial will be looking for clinical safety and efficacy endpoints and will incorporate precision medicine technology to advance our knowledge of how AMTX-100 interacts with inflammatory and anti-inflammatory gene expression. With ten clinical sites across the nation, we're excited to collect data and help improve the lives of patients experiencing symptoms associated with this chronic disease.



STUDY REVEALS GENOMIC CODE FOR SEPSIS IN THE LUNGS AND KIDNEYS



Co-Founder Jacek Hawiger, MD, PhD of Amytrx Therapeutics has led his team at Vanderbilt University Medical Center and the Nashville Veterans Affairs Medical Center recently investigated the impact of lead AMTX-100 peptide on sepsis in the lungs and kidneys.

They have demonstrated, in an animal model, how a cell-penetrating drug they developed in their lab can control the devastating inflammatory response to out-of-control infection that is the hallmark of sepsis.

Reporting August 11 in the journal *Frontiers in Immunology*, they found that sepsis caused a “massive genomic response” to infection, altering the expression of 6,237 genes in the lungs, the site of acute respiratory distress syndrome, and 5,483 genes in the kidneys, the site of acute kidney injury.

Remarkably, injections of their peptide drug, cSN50.1, “reprogrammed” the expression of 3,735 sepsis-induced genes in the lungs and 1,951 in the kidneys. This approach “paves the way for the potentially effective treatment of sepsis, one of the most prevailing and challenging complications of severe infections worldwide,” the researchers concluded.

“THE PROBLEM OF SEPSIS HAS BEEN CLOSE TO MY HEART AND MIND FOR THE PAST TWO-AND-A-HALF DECADES, SINCE MY MOTHER SUCCUMBED TO SEPSIS AS A COMPLICATION OF STROKE,” SAYS DR. HAWIGER.

Meet our CEO Dr. Matthew Gonda

Dr. Gonda heads a team of dedicated scientists and business professionals, blending industry, immunology, and peptide expertise to advance novel therapeutics for chronic diseases mediated by inflammation. Matt is a serial entrepreneur and has more than 45 years of business and R&D experience within the pharmaceutical and biotechnology industries, with extensive knowledge in biological and small molecule therapeutics. With over 300 published articles, chapters and abstracts, he is internationally recognized for his contributions to understanding the biology of HIV as the cause of AIDS and is named on 33 patents.

Dr. Gonda received his Ph.D. from The Johns Hopkins University where he studied in the School of Medicine and Bloomberg School of Hygiene and Public Health.



JOIN US IN WELCOMING OUR NEW BOARD MEMBERS!



DR. SATISH JOSHI.


DR. JOSHI IS A PEPTIDE CHEMISTS WITH OVER 20 YEARS OF EXPERIENCE IN PEPTIDE DISCOVERY, DEVELOPMENT, AND LARGE-SCALE MANUFACTURING METHODS WITH EXTENSIVE EXPERTISE IN PEPTIDE MEDICINAL CHEMISTRY AND PEPTIDE DRUG DELIVERY.

DR. MICHAEL HOWELL.

DR. HOWELL IS AN IMMUNOLOGIST WITH MORE THAN 20 YEARS OF EXPERIENCE IN THE GOVERNMENT, ACADEMIA AND THE BIOPHARMA/BIOTECH SECTORS. HE CURRENTLY IS THE PRESIDENT OF MOUNTAINEER BIOSCIENCES, INC AND CSO AT BIODURA, A PUBLICLY TRADED BIOPHARMA.



Have you heard?



We've been steadily working to advance the clinical study of our anti-inflammatory therapeutic, AMTX-100, to provide treatment options that can improve the lives of atopic dermatitis patients and overcome some of the safety issues with more recent as well as traditional treatments.


Earlier this year, our CEO Dr. Matthew Gonda brought some of our Phase 1/2a clinical data to Washington D.C. for the Revolutionizing Atopic Dermatitis (RAD) Conference to showcase how our unique peptide therapeutic AMTX-100 can do just that. We were absolutely thrilled to have that data featured in the prestigious British Journal of Dermatology.

LEARN MORE

JOIN US IN OUR JOURNEY TO COMBAT INFLAMMATION

Amytrx Pipeline

AMTX-100 Clinical Research Programs and Formulation Potential



STAY UP TO DATE

Subscribe or share this newsletter to keep you and your community in the loop with updates from Amytrx Therapeutics, the company bringing the novel anti-inflammatory peptide therapeutic AMTX-100 to market to treat a variety of inflammatory diseases.

